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Abstract
Background. Whether smoking should be regarded as a risk factor for mental disorders
remains unresolved. Prescribed psychotropic drugs can be used as indications for mental dis-
orders. We investigated how smoking was prospectively related to prescription of antipsycho-
tics, mood stabilizers, antidepressants, and anxiolytics.
Methods. Information about smoking, including the Fagerström Test for Nicotine
Dependence, and relevant confounders, were obtained from the population-based Young in
Norway Study (N = 2602), with four data collection waves between 1992 and 2006. These sur-
vey data were linked with information on prescriptions for psychotropic drugs from the com-
prehensive, nationwide Norwegian Prescription Database from 2007 to 2015.
Results. Daily smoking with high dependence in 2006 at age 28.5 (S.D. = 2.0) was associated
with filling prescriptions of antipsychotics (OR, 6.57, 95% CI 2.19–19.70, p = 0.001), mood
stabilizers (OR, 7.11, 95% CI 2.51–20.15, p < 0.001) and antidepressants (OR, 1.91, 95% CI
1.13–3.23, p = 0.016) 1–9 years later. Associations remained significant after adjustment for
a variety of potential confounders measured before the assessment of smoking, including
sociodemographic background, conduct problems, cannabis use, mental distress, and previous
prescriptions for psychotropic medications. The association between smoking and prescrip-
tion of anxiolytics was weaker and more unstable.
Conclusions. In this study of young adults, daily smoking with high dependence was asso-
ciated with later prescriptions of antipsychotics, mood stabilizers and antidepressants, indicat-
ing smoking as a risk factor for mental disorders treated with these drugs.
Introduction
Cigarette smoking is the leading cause of preventable death, with well-established causal asso-
ciations to several somatic diseases (Reitsma et al., 2017). Mental disorders are also associated
with smoking, in the sense that persons with mental disorders more often smoke compared to
persons without mental disorders (Lasser et al., 2000). Whether smoking may be a risk factor
for mental disorders, and the magnitude of this potential risk, is less clear.
Smoking prevalence among persons with schizophrenia is high, with a five-fold risk for
patients with schizophrenia to smoke compared to non-patients (De Leon & Diaz, 2005;
Salokangas, Honkonen, Stengård, Koivisto, & Hietala, 2006). Some research suggests that as
many as 60% of patients with schizophrenia smoke and that one-third smoke in the excess
of 20 cigarettes per day (Salokangas et al., 2006). The high prevalence and intensity of smoking
have long been seen as the patient’s attempt to alleviate symptoms (Jacobsen et al., 2004; Sacco
et al., 2005) and counter side-effects of medications (Goff, Henderson, & Amico, 1992). A
benchmark study by Andréasson, Engström, Allebeck, and Rydberg (1987) found that canna-
bis, but not smoking, was related to later development of schizophrenia. In contrast, two recent
meta-analyses of prospective studies suggest that smoking may be a risk factor for psychosis,
with a doubled relative risk of developing schizophrenia for smokers compared to non-
smokers and with heavier smoking associated with greater risk (Gurillo, Jauhar, Murray, &
MacCabe, 2015; Hunter, Murray, Asher, & Leonardi-Bee, 2020). However, the number of lon-
gitudinal studies addressing the issue is limited, and the two meta-analyses were each based on
only five individual studies, of which four were the same in both meta-analyses (Kendler,
Lönn, Sundquist, & Sundquist, 2015; Sørensen, Mortensen, Reinisch, & Mednick, 2011;
Weiser et al., 2004; Zammit et al., 2003).
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Smoking is two to three times more common for persons with
bipolar disorder compared to the general population (Heffner,
Strawn, DelBello, Strakowski, & Anthenelli, 2011), and smoking
prevalence in this patient group is higher than for patients with
major depression but lower than for patients with schizophrenia
(Jackson, Diaz, Lopez, & de Leon, 2015). Despite these high
rates, few prospective studies investigate smoking as a potential
risk factor for bipolar disorder. Smoking may play a mediating
role in the severity of bipolar disorder (Thomson et al., 2015),
and nicotine dependence and bipolar disorder were found in
one study to predict the onset of each other (Martínez-Ortega
et al., 2013). Also, a recent Mendelian randomization study con-
cluded that smoking can be viewed as a causal risk factor for
developing bipolar disorder (Vermeulen et al., 2021).
The relationship between smoking and depression and anxiety
seems to be bidirectional (Fluharty, Taylor, Grabski, & Munafò,
2016). There is evidence that depression increases the risk of
smoking (Khaled, Bulloch, Williams, Lavorato, & Patten, 2011),
whilst others report that smoking increases the risk of depression
(Boden, Fergusson, & Horwood, 2010; Pasco et al., 2008).
Meta-analyses find that smokers have greater odds for follow-up
incidents of depression compared to non-smokers, both when
including studies of adults (Luger, Suls, & Vander Weg, 2014)
and adolescents (Chaiton, Cohen, O’Loughlin, & Rehm, 2009).
Studies on anxiety show the same pattern: some find that anxiety
may increase the risk of later smoking (Senol, Donmez, Turkay, &
Aktekin, 2006) while other shows that smoking is a risk factor for
the development and worsening symptoms of anxiety (Cuijpers,
Smit, Ten Have, & De Graaf, 2007; Moylan et al., 2013;
Mykletun, Overland, Aarø, Liabø, & Stewart, 2008; Okeke,
Spitz, Forman, & Wilkinson, 2013; Taylor et al., 2014).
Comparison of the risk imposed by smoking on different types
of mental disorders is difficult, as there are few longitudinal stud-
ies in this area for some disorders, and single studies typically
look at only one of the mental health outcomes. The studies differ
with regard to operationalization of exposure and outcome and
to which extent they adjust for potential confounders. Studies
combining several mental health outcomes using the same
methodology would add valuable information. Also, as smoking
behavior is diverse and the risk of some mental disorders may
be higher for the heavy smokers (Hunter et al., 2020), a differen-
tiation between daily smoking with and without nicotine depend-
ence is recommended (Gurillo et al., 2015).
In this prospective longitudinal study, we investigated the rela-
tionships between smoking and later prescription of antipsycho-
tics, mood stabilizers, antidepressants and anxiolytics. We
differentiated between previous smoking and daily smoking
with a high and low degree of nicotine dependence. We included
baseline measurement of a multitude of possible confounders,
such as several variables of socio-demographic background, par-
ental smoking, conduct problems, mental distress and use of can-
nabis. To decrease the possibility of reversed causality, we finally
adjusted for prescriptions of psychotropic medications the year
before smoking was assessed.
Methods
Procedure and participants
The study was based on data from the Young in Norway study,
described in more detail elsewhere (von Soest, Bramness,
Pedersen, & Wichstrøm, 2012; von Soest, Wichstrøm, &
Kvalem, 2016). In short, the initial sample at T1 (1992) was com-
posed of students in grades 7–12 drawn from 67 junior and senior
high schools in Norway (age span 12–20 years, response rate
97%). The only exclusion criterion was a severe lack of reading
capability. Students were followed up in 1994 (T2), 1999 (T3),
and 2005–2006 (T4), with the mean age of the participants across
the four data collection waves being: T1: 15.1 (S.D. = 2.0 years), T2:
16.5, T3: 23.0 and T4: 28.5 years. The cumulative response rate
across all four waves was 69%.
At the last data collection, respondents were asked for their
consent to link the data to several registers, to which 2602 respon-
dents (90%) agreed. These 2602 respondents, 1145 men (44%)
and 1457 women (56%), who completed the assessment at T4
and consented to registry linkage, constitute the sample in the
present study.
Information about prescriptions for mental disorders was
drawn from the Norwegian Prescription Database (NorPD).
This registry is administered by the Norwegian Institute of
Public Health and contains information on all prescriptions dis-
patched to pharmacies outside of institutions, prescribed to indi-
viduals, from 2004. The database includes information about the
date of prescription filling, anatomical-therapeutic-chemical
(ATC) code of the drug (WHO, 2019), and the number of daily
defined doses. The outcome in the current study included data
from the NorPD from 1 January 2007 to 31 December 2015;
1–9 years after T4.
Attrition analysis showed that male gender (OR 1.27, 95% CI
1.15–1.40, p < 0.001), having parents with non-Norwegian coun-
tries of origin (OR 1.66, 95% CI 1.28–2.15, p < 0.001), low paren-
tal education (OR 0.86, 95% CI 0.82–0.90, p < 0.001), not growing
up with both biological parents (OR 0.81, 95% CI 0.73–0.90, p <
0.001), conduct problems at T1 (OR 1.66, 95% CI 1.45–1.90, p <
0.001), and alcohol intoxication at T1 (OR 1.05, 95% CI 1.01–1.09;
p = 0.02) were significantly related to dropout, whereas parental
smoking and mental distress at T1 were not (p > 0.05).
Measures
Smoking
Smoking history was assessed in 2005–2006 (T4) by asking
respondents whether they currently smoked daily or had done
so earlier. To examine the adequacy of the prevalence estimates
of daily smoking, we compared the data with independently
obtained official national estimates from Statistics Norway
(Statistics Norway, 2020). These comparisons showed high agree-
ment, with a slightly higher prevalence rate for our data set (23%
v. 20%) in the relevant age groups, which may relate to the lower
response (61%) in the national data set. The Fagerström Test for
Nicotine Dependence (FTND; Fagerström and Schneider, 1989;
Heatherton, Kozlowski, Frecker, and Fagerström, 1991) was
included in the questionnaire at T4 to assess nicotine dependence
by self-report. The scores range from 0 to 10 (Cronbach’s α = 0.68,
based on observations from all respondents who smoked at T4;
n = 517), and the instrument has satisfactory reliability and valid-
ity (Pomerleau, Carton, Lutzke, Flessland, & Pomerleau, 1994). In
most analyses we used a dichotomized measure, where scores of 4
or higher is considered to indicate nicotine dependence (Huang,
Lin, & Wang, 2008). Based on self-reported smoking and the
FTND at T4, we divided the material into four categories: Those
who had never smoked daily; those who had smoked daily at
least once in their lifetime, but not in the last 12 months; those
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who smoked daily with low dependence (FTDN <4); and those
who smoked daily with high dependence (FTDN ⩾4).
Prescription of psychotropic drugs
Subjects were categorized according to ATC-codes in mutually
exclusive groups as receiving antipsychotics, mood stabilizers,
antidepressants or anxiolytics during the 9-year period from
2007 to 2015. A fifth group was created to capture prescriptions
that due to dose and type of drug were evaluated to be psycho-
tropic drugs used for other conditions than a mental disorder
(mainly nausea, sleep problems or epilepsy). In addition to
obtaining prescription data as an outcome from the 9-year period
from 2007 to 2015, prescription data were also obtained from
2004, the year before smoking was assessed. The reason for the
1–9 years duration of the follow-up period was that the prescrip-
tion data used in this study contained information up until 2015.
Hierarchical decision rules were used for assigning a prescrip-
tion category when persons had received medications from more
than one category. The hierarchy of decision rules was based on
the fact that some types of medications are almost exclusively
used for the treatment of a specific psychiatric disorder, such as
lithium for bipolar disorder, independent of additional prescrip-
tion of other types of psychotropic drugs. These psychotropic
drugs were placed on the top in the decision hierarchy. In con-
trast, other medications may be used for the treatment of a spe-
cific psychiatric disorder only when not used in combination
with other drugs. For example, antidepressants prescription may
indicate treatment for unipolar depression, but only when not
used in combination with lithium, as this would indicate the treat-
ment of bipolar disorder. These types of medications were placed
towards the bottom of the decision hierarchy. As a result, decision
rules for assigning a prescription category were hierarchical pri-
oritizing in the following order: (1) mood stabilizers, (2) antipsy-
chotics, (3) antidepressants, (4) anxiolytics and (5) psychotropic
drugs prescribed on other indications. To exemplify, persons
with prescriptions of both antidepressants and mood stabilizers
would have been categorized as receiving mood stabilizers.
Some exceptions from the general rules were made to account
for particular pharmacological combinations, such as only low-
dose prescriptions and cases of only one prescription. The cat-
egorization principles were constructed without knowledge
about smoking status, with the purpose to optimize the prescrip-
tion categories as proxies for underlying mental disorders. A
detailed description of the principles is provided in the
supplement.
Socio-demographics
Age, gender and country of birth (Norway or other) were assessed
at T1. Parental education was assessed at the same time point and
was classified into five levels from up to 9 years of basic education
(1) to more than 3 years of university education (5) for the parent
with the highest education. We also asked whether the respondent
was living with both biological parents or not at T1. At T3, respon-
dents were asked whether their father and mother smoked daily
during their childhood or not, and we contrasted those who
had at least one parent who smoked in childhood with those
who had no smoking parent.
Conduct problems and use of alcohol and cannabis
We used a 15-item measure of conduct problems at T1, which
approximates diagnostic criteria for conduct disorder in the
DSM-III-R (Wichstrom, Skogen, & Øia, 1996). Response options
ranged from 1 (never) to 6 (more than 50 times). Mean scores
across all items were computed (Cronbach’s α = 0.75, based on
n = 2367 observations). We assessed the number of alcohol intoxi-
cation episodes at T1 by asking how often respondents had
drunken so much that they felt clearly intoxicated during the pre-
vious 12 months. Response options ranged from 1 (never) to 6
(more than 50 times). We also assessed at T4 whether respondents
had used cannabis at least once the previous 12 months or not.
Mental distress
Mental distress was measured at T1 by 12 items from the Hopkins
Symptom Checklist (Derogatis, Lipman, Rickels, Uhlenhuth, &
Covi, 1974). The measure asks for ratings of symptoms of depres-
sion and anxiety the preceding week and applies a 4-point scale
with the response options from 1 (not bothered at all) to 4
(extremely bothered). The items have been used in several studies
to measure mental distress and have favorable psychometric prop-
erties (Pedersen & von Soest, 2009). Mean scores were computed
and internal consistency was high (Cronbach’s α = 0.85, based on
n = 2397 observations).
Analyses
Multinomial logistic regression analysis was conducted with pre-
scription as dependent variable and smoking as the independent
variable. The categories of ‘antipsychotics’, ‘mood stabilizers’,
‘antidepressants’, ‘anxiolytics’ and ‘psychotropic drugs on other
indications’ were all compared to the reference category ‘no psy-
chotropic drugs’. We compared levels of nicotine use (‘smoked
daily before but not now’, ‘daily smoking, low dependence’,
‘daily smoking, high dependence’) with the reference category
‘never smoked daily’. We adjusted for potential confounders in
four steps by including several indicators of socio-demographic
background and parental smoking behavior in a first step, adding
conduct problems and cannabis use in a second step, and adding
mental distress in the third step as covariates. Moreover, in a
fourth step, we additionally added a dummy variable indicating
whether or not respondents had received prescriptions of psycho-
tropic drugs in 2004 (n = 134), the year before information about
smoking was obtained, thereby controlling for the possibility of
prescriptions of psychotropic drugs preceding smoking.
A robust maximum likelihood estimator (MLR) was used in all
analyses, thereby accounting for potential multivariate non-
normality (Muthén & Muthén, 2012). Because respondents
were originally recruited from 67 different schools, potential non-
independence of observations owing to school clusters was
addressed by estimating parameters by maximizing a weighted
log-likelihood function, whereas standard error estimations were
performed with a sandwich estimator. Missing data were handled
by means of full information maximum likelihood estimation,
thereby providing missing data routines that are considered to
be state of the art (Muthén & Muthén, 2012; Schafer &
Graham, 2002). The statistical program Mplus 7.4 was used for
all regression analyses.
Results
Of the total sample of 2602 individuals, 1468 (56.7%) had never
been daily smokers, 606 (23.4) were former daily smokers, 305
(11.8%) were daily smokers with low dependence and 212
(8.2%) were daily smokers with high dependence. Data on smok-
ing was missing for 11 participants. Based on the dominating type
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of prescriptions during the 9 year follow-up period, 33 individuals
(1.3%) were categorized as receivers of antipsychotics, 36 indivi-
duals (1.4%) as mood stabilizer users, 233 individuals (9.0%)
were prescribed antidepressants, 102 individuals (3.9%) received
anxiolytics and 84 persons (3.2%) had been prescribed psycho-
tropic drugs for presumably other reasons than a mental disorder
(Table 1). The number of individuals who had not received any
prescriptions of psychotropic drugs was 2114 (81.4%).
A total of 187 individuals had during the 9-year period
received prescriptions from more than one prescription category.
Among these, 129 persons had received a prescription of two pre-
scription categories, 44 persons had received prescriptions from
three prescription categories and 14 persons had received pre-
scriptions from all four prescription categories. Information con-
cerning the types and number of prescriptions of multiple
categories of psychotropic drugs is provided in online
Supplementary Tables S1 and S2.
Those who had not filled prescriptions for any psychotropic
drugs during follow-up smoked less, had less often parents who
smoked and reported less use of cannabis and lower mental dis-
tress, compared to those with some type of prescription of psy-
chotropic medication (Table 1). There were differences between
the smoking categories on all variables except being born in
Norway, with a pattern of most healthy and protective back-
ground among those who had never been daily smokers and
most unfavorable background among the daily smokers with
high dependence (Table 2).
The unadjusted results of the multinomial regression analyses
showed a strong association between daily smoking with high
dependence and later prescription of antipsychotics and mood
stabilizers, and a significant but weaker association for daily
smoking with low dependence and antipsychotics and mood
stabilizers (Table 3). The associations between daily smoking
and antidepressants and anxiolytics were also significant, but
with smaller effect sizes than those found for the association
with antipsychotics and mood stabilizers.
Through the four steps of adjustment, the pattern remained
the same, with the final model estimating significant association
between daily smoking with high dependence and prescription
of antipsychotics (OR = 6.57, 95% CI 2.19–19.70, p = 0.001),
mood stabilizers (OR = 7.11, 95% CI 2.51–20.15, p < 0.001) and
antidepressants (OR = 1.91, 95% CI 1.13–3.23, p = 0.016). The
association between daily smoking and prescription of anxiolytics
was significant in some but not all models, and in the final model,
the association was only significant for smoking with low
dependence.
Daily smoking with high dependence was associated with later
prescription of psychotropic drugs on other indications through
all four steps of adjustment, with an OR = 2.41 (95% CI 1.30–
4.48, p = 0.005) in the final model.
Due to somewhat low numbers in some prescription categor-
ies, we conducted additional analyses where daily smokers with
high and low dependence were merged into one category. A
new set of multinomial regressions was performed with the new
smoking variable as predictor and results are presented in online
Supplementary Table S4. Comparable results to the results of high
and low dependence in Table 3 were obtained, with odds ratios
generally between the odds ratios for high and low dependence
and with more narrow confidence intervals.
Eight individuals had only received prescriptions of valproic
acid or lamotrigine. Based on dose and type of drug it was not
viable to decide whether this medication was prescribed for
epilepsy or bipolar disorder. The reported results are based on a
conservative categorization, defining these cases as epilepsy and
thus in the category ‘psychotropic drugs on other indication’.
Additional analyses with these individuals categorized as mood
stabilizers yielded results very similar to those reported in
Table 3, with an OR = 5.87 (95% CI 2.41–14.28, p < 0.001) for
the mood stabilizers category in the final model (results not
reported in the table).
To obtain information about the suitability of the logistic
regression analyses conducted in Table 3, we conducted
Hosmer–Lemeshow goodness of fit tests. As these tests cannot
easily be conducted for multinomial logistic regression analyses,
we conducted simple logistic regression analyses for each pre-
scription category where participants with prescriptions from
this category were contrasted with all other participants. All five
tests yielded non-significant p-values (p > 0.05), thereby indicat-
ing a satisfactory model fit. Moreover, when estimating
Variance Inflation Factors for all independent variables all values
showed to be below 2, thereby indicating no issues with multicol-
linearity. Finally, we estimated Cook’s Distance measures to
examine the possible influence of outliers on the results. We iden-
tified five respondents with values > 1 (see Hosmer, Lemeshow,
and Sturdivant, 2013). However, excluding observations from
these respondents from the analyses did not change the results
substantially.
Discussion
In this study, linking a population-based investigation with data
from an administrative register, we found that daily smoking
was prospectively associated with later prescriptions of all classes
of psychotropic drugs. The associations were distinctly stronger
for those who reported higher nicotine dependence. The associa-
tions were significant after adjustment for a series of covariates,
including baseline mental distress, cannabis use and prescriptions
for psychotropic drugs the year before smoking was assessed. The
effect sizes were larger for antipsychotics and mood stabilizers
than for the other drugs.
The prospective association between nicotine dependence and
antipsychotic prescriptions found in this study is in line with the
more recent understanding of smoking as a potential risk factor
for schizophrenia (Gurillo et al., 2015; Hunter et al., 2020). The
marked larger effect sizes for those with a high level of depend-
ence relative to other smokers indicate a dose–response relation-
ship, which supports the notion of a causal association between
smoking and psychotic disorders (Scott et al., 2018; Wium-
Andersen, Ørsted, & Nordestgaard, 2015). The sixfold increase
in risk among the daily smokers with high dependence may
have to do with capturing the heaviest smokers, and we know
that persons with schizophrenia smoke excessively (Salokangas
et al., 2006).
Though it has been suggested that smoking may contribute to
the development of the bipolar disorder (Slyepchenko, Brunoni,
McIntyre, Quevedo, & Carvalho, 2016), the evidence of smoking
as a risk factor for bipolar disorder is still scarce (Martínez-Ortega
et al., 2013; Vermeulen et al., 2021). It is a previously well-
described observation that persons with bipolar disorders tend
to smoke (Heffner et al., 2011; Lasser et al., 2000) and the associ-
ation between smoking and mood stabilizers found in this study,
with a sevenfold increase in risk after adjustment for all confoun-
ders, suggests that smoking may be a risk factor for bipolar
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Table 1. Smoking, socio-demographics, conduct problems, drug use and mental distress according to filling prescriptions for psychotropic drugs




n = 2114 (81.2%) n = 33 (1.3%) n = 36 (1.4%) n = 233 (9.0%) n = 102 (3.9%) n = 84 (3.2%) χ2/F p
Smoking
Never smoked daily (T4) n (%) 1273 (60.4%) 9 (27.3%) 10 (27.8%) 94 (40.5%) 44 (43.6%) 38 (45.8%)
Smoked daily before but not now (T4) n (%) 475 (22.6%) 7 (21.2%) 7 (19.4%) 64 (27.6%) 27 (26.7%) 26 (31.3%)
Daily smoking, low dependence (T4) n (%) 227 (10.8%) 6 (18.2%) 8 (22.2%) 39 (16.8%) 18 (17.8%) 7 (8.4%)
Daily smoking, high dependence (T4) n (%) 131 (6.2%) 11 (33.3%) 11 (30.6%) 35 (15.1%) 12 (11.9%) 12 (14.5%)
Socio-demographics
Female gender (T1) n (%) 1137 (53.8%) 15 (45.5%) 25 (69.4%) 154 (66.1%) 69 (67.6%) 57 (67.9%) 28.39 <0.001
Age (T1) Mean (S.D.) 15.24 (1.87) 14.88 (3.18) 15.14 (3.04) 15.28 (2.15) 15.37 (1.92) 15.37 (2.41) 0.43 0.828
Born in Norway (T1) n (%) 1925 (97.0%) 27 (93.1%) 32 (94.1%) 214 (96.8%) 94 (96.9%) 77 (98.7%) 3.27 0.659
Parental education (T1) Mean (S.D.) 3.42 (1.12) 3.08 (1.13) 3.33 (1.18) 3.16 (1.07) 3.33 (1.12) 3.21 (1.10) 2.60 0.024
Living with both parents (T1) n (%) 1450 (71.5%) 20 (64.5%) 24 (70.6%) 130 (57.5%) 56 (55.4%) 56 (70.0%) 28.74 <0.001
One or both parents smoked (T3) n (%) 849 (46.1%) 16 (64.0%) 20 (58.8%) 125 (60.5%) 46 (50.5%) 36 (48.0%) 23.74 <0.001
Conduct problems and drug use
Conduct problems (T1) Mean (S.D.) 1.34 (0.37) 1.36 (0.35) 1.37 (0.46) 1.41 (0.40) 1.45 (0.53) 1.41 (0.45) 2.71 0.019
Alcohol intoxication (T1) Mean (S.D.) 1.88 (1.42) 1.54 (1.10) 1.57 (1.25) 2.11 (1.46) 2.10 (1.61) 2.09 (1.47) 2.29 0.043
Cannabis use at (T4) n (%) 220 (10.6%) 13 (41.9%) 11 (33.3%) 43 (18.9%) 17 (17.0%) 13 (15.7%) 55.48 <0.001
Mental health and previous prescriptions
Mental distress (T1) Mean (S.D.) 1.57 (0.45) 1.70 (0.55) 1.65 (0.48) 1.80 (0.53) 1.64 (0.44) 1.65 (0.45) 10.75 <0.001
Psychotropic drug prescription in 2004 n (%) 40 (1.9%) 21 (36.4%) 19 (52.8%) 42 (18.0%) 10 (9.8%) 11 (13.1%) 373.40 <0.001
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disorder. This should encourage further investigations on the
association between smoking and bipolar disorder.
The results of an association between nicotine dependence and
prescriptions of antidepressants are in line with results from pre-
vious research about the relationship between smoking and
depression (Chaiton et al., 2009; Luger et al., 2014), and of similar
effect sizes. Also, a study on the same cohort as the one used in
the present study, but without the linkage to the prescription
database, found a prospective association between nicotine
dependence and later symptoms of depression (Pedersen & von
Soest, 2009). Our results demonstrated somewhat stronger effect
sizes for those with high relative to those with low dependence
in most models and similar patterns have been found when
using a graded nicotine exposure (Flensborg-Madsen et al.,
2011). However, results from Mendelian randomization studies
provide conflicting results about the causal effect of smoking on
depression (Köhler et al., 2018; Wium-Andersen et al., 2015;
Wootton et al., 2020).
Smoking has previously been found to increase the risk of later
development of certain specific anxiety disorders, such as panic
disorder and generalized anxiety disorder (Moylan, Jacka, Pasco,
& Berk, 2012). Our results indicate that daily smoking is asso-
ciated with a later prescription of anxiolytics, but with relatively
small and uncertain effect sizes.
The association between daily dependent smoking and pre-
scriptions presumably on other indication than a mental disorder
may point to the somatic and lifestyle conditions associated with
smoking (Reitsma et al., 2017). This outcome category may con-
tain many symptoms and maladies and may be a poor proxy for
any specific underlying condition. It is therefore difficult to con-
clude about the importance of this result.
A study limitation is that we do not know how good a proxy
our classification of prescriptions is for mental disorders. The
proportion receiving treatment of those who have a mental
disorder may not be equal across diagnostic categories, and the
treatment coverage is probably highest for psychotic disorders
(Kohn, Saxena, Levav, & Saraceno, 2004). The anxiolytics cat-
egory may involve the crudest approximation, as benzodiazepines
are also used to treat several other disorders not related to anxiety,
and other drugs, such as antidepressants, are used to treat anxiety
disorders. The criteria for classification in this paper were based
on clinical knowledge on drug use, but as most drugs have several
uses, each individual case was reviewed to increase the likelihood
of correct approximations. We find it unlikely that erroneous cat-
egorization could explain a large share of the difference in risk
found in the present study. Also, receiving a prescription of a psy-
chotropic drug has been used as an indirect measure of mental
disorders in several previous studies (McKenzie, Murray, &
Booth, 2013; Mok et al., 2013; Rognli, Bramness, & von Soest,
2020; Wium-Andersen et al., 2015).
The prevalence of daily smoking in Norway has declined
dramatically during the last 50 years and is now just below 10%
(Statistics Norway, 2020). The current data on smoking were
obtained in 2006, at a time when this behavior was viewed as
increasingly more unacceptable and stigmatized (Stuber, Galea,
& Link, 2008). The change in smoking towards a more marginal
phenomenon may imply more social disadvantage among
smokers relative to non-smokers (Hiscock, Bauld, Amos, Fidler,
& Munafò, 2012). Though we adjusted for socioeconomic back-
ground defined as parental education, we acknowledge that
some of the effect of smoking on the different psychotropic out-
comes could be an effect of residual confounding in terms of
unmeasured social hardship. Also, we could not assess changes
in smoking during follow-up and cannot rule out the possibility
that mental disorders were triggered by smoking cessation.
As the attrition analyses showed, variables such as conduct
problems and alcohol intoxication at T1 and low parental educa-
tion were associated with dropout, meaning that our sample











n = 1468 (56.7%) 606 (23.4%) n = 305 (11.8%) n = 212 (8.2%) χ2/F p
Socio-demographics
Female gender (T1) n (%) 787 (53.6%) 366 (60.4%) 192 (63.0%) 107 (50.5%) 16.77 0.001
Age (T1) Mean (S.D.) 15.26 (1.81) 15.42 (2.15) 14.95 (1.97) 15.04 (2.27) 4.66 0.003
Born in Norway (T1) n (%) 1336 (97.1%) 551 (96.7%) 281 (96.6%) 190 (97.4%) 0.55 0.907
Parental education (T1) Mean (S.D.) 3.43 (1.10) 3.38 (1.14) 3.38 (1.09) 3.02 (1.17) 6.26 <0.001
Living with both parents (T1) n (%) 1077 (75.8%) 346 (60.6%) 205 (69.7%) 100 (48.8%) 89.67 <0.001
One or both parents smoked (T3) n (%) 536 (41.4%) 267 (50.8%) 154 (59.7%) 132 (73.3%) 84.37 <0.001
Conduct problems and drug use
Conduct problems (T1) Mean (S.D.) 1.27 (0.30) 1.46 (0.46) 1.46 (0.42) 1.50 (0.51) 51.38 <0.001
Alcohol intoxication (T1) Mean (S.D.) 1.63 (1.22) 2.31 (1.62) 2.20 (1.53) 2.31 (1.59) 42.27 <0.001
Cannabis use (T4) n (%) 101 (7.0%) 86 (14.6%) 59 (20.1%) 14 (7.7%) 44.73 <0.001
Mental health and previous prescriptions
Mental distress (T1) Mean (S.D.) 1.55 (0.43) 1.64 (0.49) 1.65 (0.48) 1.73 (0.54) 13.69 <0.001
Psychotropic drug prescription in 2004 n (%) 54 (3.7%) 31 (5.1%) 16 (5.2%) 33 (15.6%) 53.39 <0.001
aDifference tests conducted by means of χ2 (categorical variables) and analysis of variance (continuous variables).
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Table 3. Results of multinomial regression analyses with the prescription of psychotropic drugs as an outcome
Antipsychotics Mood stabilizers Antidepressants Anxiolytics
Psychotropic drugs on other
indications
n = 33 n = 36 n = 233 n = 102 n = 84
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Baseline Model: Unadjusted associations
Smoking
Never smoked daily (reference) (reference) (reference) (reference) (reference)
Smoked daily before but not now 2.08 0.86–5.08 0.106 1.88 0.58–6.03 0.292 1.82 1.34–2.48 <0.001 1.64 0.95–2.84 0.075 1.83 1.14–2.95 0.013
Daily smoking, low dependence 3.74 1.16–12.10 0.028 4.49 1.58–12.79 0.005 2.33 1.68–3.22 <0.001 2.29 1.30–4.04 0.004 1.03 0.50–2.12 0.930
Daily smoking, high dependence 11.90 4.88–29.06 <0.001 10.71 4.14–27.69 <0.001 3.62 2.34–5.60 <0.001 2.65 1.42–4.96 0.002 3.07 1.71–5.53 <0.001
Model 1: Adjustment for socio-demographics
Smoking
Never smoked daily (reference) (reference) (reference) (reference) (reference)
Smoked daily before but not now 2.09 0.85–5.17 0.109 1.85 0.54–6.41 0.330 1.61 1.17–2.20 0.003 1.45 0.82–2.58 0.205 1.80 1.13–2.84 0.013
Daily smoking, low dependence 3.53 1.03–12.14 0.045 4.21 1.44–2.29 0.008 2.05 1.47–2.86 <0.001 2.17 1.23–3.80 0.007 1.01 0.48–2.12 0.978
Daily smoking, high dependence 10.28 4.04–26.19 <0.001 11.60 4.06–3.12 <0.001 2.84 1.75–4.60 <0.001 2.34 1.21–4.54 0.012 3.18 1.78–5.67 <0.001
Model 2: Additional adjustment for conduct problems and drug use
Smoking
Never smoked daily (reference) (reference) (reference) (reference) (reference)
Smoked daily before but not now 2.19 0.83–5.75 0.113 1.94 0.60–6.28 0.268 1.50 1.06–2.11 0.020 1.31 0.71–2.42 0.394 1.63 1.01–2.63 0.046
Daily smoking, low dependence 3.59 1.06–12.14 0.040 4.21 1.36–13.05 0.013 1.85 1.33–2.58 <0.001 1.92 1.01–3.64 0.045 0.89 0.41–1.91 0.762
Daily smoking, high dependence 8.88 3.30–23.90 <0.001 10.07 3.63–27.90 <0.001 2.42 1.45–4.01 0.001 1.98 1.02–3.86 0.045 2.70 1.48–4.91 0.001
Model 3: Additional adjustment for mental distress
Smoking
Never smoked daily (reference) (reference) (reference) (reference) (reference)
Smoked daily before but not now 2.15 0.82–5.61 0.119 1.92 0.59–6.26 0.278 1.44 1.01–2.05 0.042 1.31 0.71–2.41 0.390 1.62 1.00–2.61 0.048
Daily smoking, low dependence 3.55 1.04–12.16 0.043 4.16 1.33–12.97 0.014 1.78 1.28–2.48 0.001 1.92 1.02–3.61 0.044 0.88 0.41–1.90 0.744
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defined at T4 may have been a selection of the more privileged
and untroubled youth. It is unlikely that this has affected the asso-
ciation between smoking and later psychotropic prescriptions in a
substantial way.
We tried to reduce the probability of reversed causality by
adjusting for early mental distress and previous prescriptions of
psychotropic drugs, but such efforts may still be insufficient. It
is well known that some mental disorders develop slowly, and
the prodromal phase for psychosis may last for years (Yung &
McGorry, 1996). Smoking may have been an attempt to regulate
emotional distress among vulnerable individuals even long before
the manifestation, or at least medication, of a mental disorder
(Gehricke et al., 2007; Khantzian, 1997).
Despite these limitations, there is an advantage of using this
prescription database, in that, all treated patients, from both pri-
mary health care and specialized health care are included. Norway
is a country with a wide-ranging publicly financed health care sys-
tem, and access to health care and prescriptions is based on illness
severity, not on the private economy (Barber et al., 2017; Nordic
Medico-Statistical Committee, 2017).
The FTND is an established measure of dependence and
allows for a differentiation of the level of dependence among
daily smokers (Heatherton et al., 1991). The increase in effect
size for smokers with high dependence compared to other
smokers, seen particularly pronounced for mood stabilizers and
antipsychotics but also for antidepressants and anxiolytics, can
be understood as a dose–response relationship, which is crucial
for inferring causality (Hill, 1965).
This study is informative as it has a relatively large population-
based sample, includes numerous relevant confounders, has a
graded measure of nicotine dependence, and expands the knowl-
edge from previous studies by using prescription data as an out-
come. It is also an advantage that the study includes several types
of mental health outcomes, allowing for comparison across differ-
ent disorders. Though causal inference cannot be made based on
observational data, the results indicate that smoking increases the
risk of psychosis, bipolar disorder and depression, and perhaps
also anxiety. The harmful effect of smoking not only on physical
health but also on mental health should encourage mental health
services to encompass health habits such as smoking in their
treatment approach.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291720005401.
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